Published in J Gen Virol on December 01, 1982
Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob Agents Chemother (1988) 1.57
Molecular and biological characterization of a herpes simplex virus type 1 (HSV-1) neuroinvasiveness gene. J Exp Med (1990) 1.36
Disruption of HDAC/CoREST/REST repressor by dnREST reduces genome silencing and increases virulence of herpes simplex virus. Proc Natl Acad Sci U S A (2010) 1.19
Pathogenesis of a lethal mixed infection in mice with two nonneuroinvasive herpes simplex virus strains. J Virol (1988) 1.08
Glycoprotein B is a specific determinant of herpes simplex virus type 1 neuroinvasiveness. J Virol (1993) 1.06
Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob Agents Chemother (1993) 0.96
Genetically determined resistance to murine cytomegalovirus and herpes simplex virus in newborn mice. J Virol (1986) 0.96
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26
Antiviral effects of recombinant tumour necrosis factor in vitro. Nature (1986) 3.25
The immunobiology of zinc. Immunol Today (1997) 2.93
High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis (1998) 2.48
Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46
Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40
Short-term effects of atorvastatin on C-reactive protein. Eur Heart J (2002) 2.15
Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum. J Immunol (1975) 2.13
Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet (1994) 2.12
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (2004) 2.07
Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol (1983) 2.06
Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med (1992) 1.99
Herpes simplex virus type 1 glycoprotein E is not indispensable for viral infectivity. J Virol (1987) 1.92
Sequence of the putative origin of replication in the UL region of herpes simplex virus type 1 ANG DNA. J Gen Virol (1984) 1.85
Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79
An unusual defective genotype derived from herpes simplex virus strain ANG. Intervirology (1977) 1.75
Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol (2001) 1.74
Mutations in the type IV collagen alpha 3 (COL4A3) gene in autosomal recessive Alport syndrome. Hum Mol Genet (1994) 1.69
Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. Transfus Med (2000) 1.67
Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66
Origin of two different classes of defective HSV-1 Angelotti DNA. Nucleic Acids Res (1979) 1.62
Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62
Identification of COL4A5 defects in Alport's syndrome by immunohistochemistry of skin. Kidney Int (1999) 1.61
Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction. Transfusion (1992) 1.60
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58
Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand (1988) 1.57
Interferon treatment inhibits onset of herpes simplex virus immediate-early transcription. Virology (1988) 1.55
The glycosaminoglycan content of renal basement membranes in the congenital nephrotic syndrome of the Finnish type. Pediatr Nephrol (1992) 1.55
Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol (1996) 1.55
Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol (1976) 1.53
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50
Altered cytokine production in the elderly. Mech Ageing Dev (1998) 1.47
Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol (1979) 1.46
Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology (1998) 1.46
Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity. J Virol (1985) 1.45
Production of immune interferon by murine T-cell clones from long-term cultures. Nature (1981) 1.45
Small bacteriophages. Adv Virus Res (1966) 1.45
Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis. Eur J Pediatr (1992) 1.44
Identification of a novel dendritic cell-like subset of CD64(+) / CD16(+) blood monocytes. Eur J Immunol (2001) 1.42
Renal allograft rejection and antibodies to epithelial cells. Lancet (1992) 1.42
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer (2001) 1.42
Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry (1996) 1.41
[An interuniversity comparison of the supervision of doctoral candidates--should the promotion procedures be changed?]. Dtsch Med Wochenschr (2000) 1.40
Virus-specific basic phosphoproteins associated with herpes simplex virus type a (HSV-1) particles and the chromatin of HSV-1-infected cells. J Gen Virol (1980) 1.40
Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity. J Virol (1984) 1.39
Adequate dialysis? Measurement of KT/V in a pediatric peritoneal dialysis population. Perit Dial Int (1997) 1.39
Coincidence of neonatal alloimmune thrombocytopenia and maternal anti-D immunization: case report. Br J Haematol (1998) 1.37
The detection of human cytomegalovirus immediate early antigen in peripheral blood leucocytes. J Immunol Methods (1991) 1.35
Kinetics of the Zn 2+ - stimulation of human peripheral lmphocytes in vitro. Proc Soc Exp Biol Med (1971) 1.34
The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods (2000) 1.34
Gender differences in Parkinson's disease symptom profile. Acta Neurol Scand (2000) 1.30
Identification of herpes simplex virus type 1 (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes. J Immunol (1985) 1.28
Genetic variability of herpes simplex virus: development of a pathogenic variant during passaging of a nonpathogenic herpes simplex virus type 1 virus strain in mouse brain. J Virol (1983) 1.27
Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase. J Gen Virol (1988) 1.26
Experimental infection of inbred mice with herpes simplex virus type 1. I. Investigation of humoral and cellular immunity and of interferon induction. J Gen Virol (1981) 1.25
Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta. J Interferon Cytokine Res (1999) 1.24
In vitro mitogenic stimulation of murine spleen cells by herpes simplex virus. J Immunol (1978) 1.24
Replication of herpes simplex virus in human T lymphocytes: characterization of the viral target cell. J Immunol (1984) 1.24
High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res (2010) 1.23
Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res (1990) 1.23
Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience (2007) 1.23
Zinc-altered immune function and cytokine production. J Nutr (2000) 1.22
Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr (1999) 1.22
Benign familial hematuria due to mutation of the type IV collagen alpha4 gene. J Clin Invest (1996) 1.22
The effects of general anesthesia on human peripheral immune cell distribution and cytokine production. Clin Immunol Immunopathol (1997) 1.21
Amplification of a short nucleotide sequence in the repeat units of defective herpes simplex virus type 1 Angelotti DNA. J Virol (1981) 1.21
Prostaglandin synthesis in spleen cell cultures of mice injected with Corynebacterium parvum. Cell Immunol (1978) 1.20
Human cytomegalovirus replicates in primary human bone marrow cells. J Gen Virol (1986) 1.18
Cytokine production and serum proteins in depression. Scand J Immunol (1995) 1.18
Replacement of glycoprotein B gene sequences in herpes simplex virus type 1 strain ANG by corresponding sequences of the strain KOS causes changes of plaque morphology and neuropathogenicity. J Gen Virol (1987) 1.18
Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol (1993) 1.18
Evidence for a functional cytoprotective effect produced by antacids in the rat stomach. Eur J Pharmacol (1983) 1.17
A herpes simplex virus type 1 mutant with a deletion in the polypeptide-coding sequences of the ICP4 gene. J Gen Virol (1985) 1.16
Pokeweed mitogen-, concanavalin A-, and phytohemagglutinin-induced development of cytotoxic effector lymphocytes. An evaluation of the mechanisms of T cell-mediated cytotoxicity. J Exp Med (1973) 1.16
Rapid HLA-DRB1 genotyping by nested PCR amplification. Tissue Antigens (1992) 1.16
Synthesis and packaging of herpes simplex virus DNA in the course of virus passages at high multiplicity. Intervirology (1978) 1.16
The role of interferon in the resistance of C57BL/6 mice to various doses of herpes simplex virus type 1. J Infect Dis (1982) 1.16
Specificity of human natural killer cells in limiting dilution culture for determinants of herpes simplex virus type 1 glycoproteins. J Virol (1986) 1.16
The clinical spectrum of type IV collagen mutations. Hum Mutat (1997) 1.16
Inhibition of the mixed lymphocyte culture by peritoneal exudate cells. Cell Immunol (1976) 1.15
Stimulation of chicken lymphocytes in a serum-free medium. Cell Immunol (1972) 1.15
Mycoplasma contamination in human tumor cell lines: effect on interferon induction and susceptibility to natural killing. J Immunol (1981) 1.13
Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes (1994) 1.13
Spread of herpes simplex virus (HSV) strains SC16, ANG, ANGpath and its glyC minus and GlyE minus mutants in DBA-2 mice. Acta Virol (1990) 1.12